Alector halts mid-stage trial for Alzheimer's candidate developed with GSK
Source: SeekingAlpha
2026-04-30 14:01:30 ET
More on Alector, GSK
- GSK plc (GSK) Q1 2026 Earnings Call Transcript
- GSK plc 2026 Q1 - Results - Earnings Call Presentation
- GSK: 'Strong Buy' On Mo-Rez Oncology Expansion Potential
- GSK declares $0.44/ADS or 17p/share dividend
- GSK posts Q1 beat as HIV and cancer drugs offset weakness in general medicines
Read the full article on Seeking Alpha
For further details see:
Alector halts mid-stage trial for Alzheimer’s candidate developed with GSK
GSK plc American Depositary Shares (Each representing two)
NASDAQ: GSK
GSK Trading
1.21% G/L:
$52.37 Last:
2,698,925 Volume:
$51.91 Open:
GSK Latest News
March 13, 2026 11:44:00 am
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18-49 Years at Increased Risk
February 23, 2026 01:13:00 pm
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
GSK Stock Data
$120,291,791,432
2,019,018,428
0.4%
538
N/A
Pharmaceuticals
Healthcare
GB
London
